RATIONALE: IL-33 is produced by tissue cells, such as airway epithelial cells and endothelial cells, and has been implicated in the development of Th2-type inflammatory responses in mucosal organs. However, the roles for IL-4 in the development of IL-33-mediated airway immunity are unknown. METHODS: Naïve 4get, BALB/cJ (WT) and IL-4 knockout (IL-4 KO) mice were exposed intranasally to a model antigen, endotoxin-free ovalbumin (OVA), with or without IL-33. In vitro splenocyte recall responses to OVA and intracellular expression of cytokines, as well as in vivo airway responses to intranasal challenge with OVA, were studied. RESULTS: Four days after exposure to OVA plus IL-33, naïve 4get mice showed IL-4 expression by CD4+ T cells. After 2 weeks, this response was followed by robust development of OVA antigen-specific, Th2-type CD4+ T cells. Intranasal OVA challenge of WT mice, previously exposed to OVA plus IL-33, provoked airway Th2 cytokine production and eosinophilia. In contrast, intranasal OVA challenge of IL-4 KO mice, previously exposed to OVA plus IL-33, partially impaired the development of OVA-specific Th2-type CD4+ T cells, but enhanced the development of Th17-type CD4+ T cells. These mice also developed airway neutrophilia accompanied by increased airway production of IL-12p40, IL-17 and keratinocyte-derived chemokine. CONCLUSIONS: IL-33 may serve as a potent airway mucosal adjuvant to induce adaptive T cell responses to inhaled antigens. When airways are exposed to IL-33, IL-4 may play a pivotal role to direct to the development of either Th2- or Th17-type CD4+ T cells.